January 22-24, 2019

San Francisco, CA

View Event Guide


Challenges, Insights, and Future Directions for
Experimental Models in Cancer Immunotherapy

Tuesday, January 22


Understanding tumor placement, immune composition, response to treatment, and molecular characterization for the model of interest can be invaluable when designing the most appropriate study for your research goals. However, major issues remain not just in selecting and optimizing models and tools for cancer immunotherapy research but in selecting who to work with and when.

Discussions in this session will centre on:

• The range of current IO models available amongst their  strengths and weaknesses
• Mouse syngeneic models, their genetic backgrounds and use in  IO for mono or combination  therapy
• How to identify, select and work with model developers and  CRO’s available

Your workshop leader:


Shiva Kazerounian
Principal Scientist, In Vivo Pharmacology Lead
Berg Pharma

Evaluating Immunomodulation Therapeutics In Vivo in Translationally Relevant Humanized PBMC NSG Mice

Tuesday, January 22


Workshop participants will learn how to study immunomodulation pathways in human peripheral blood mononuclear cell (PBMC) engraftment in immunodeficiency NSG mice, including changes in T helper and effector populations during GvHD progression. Data will also be presented showing the utility of the platform to test human immuno-modulatory therapeutics in vivo.

Utilizing Translationally Relevant Mouse Models to Study Immuno-oncology Pathways and Mechanisms of Action


Attendees will learn about the utilization of various NSG mouse models and how pre-clinical scientists are utilizing the models to assess pre-clinical efficacy and better understand mechanisms of action of immuno-oncology compounds. We will discuss the potency of utilizing the NSG models to improve translational relevance as well as the variability of response rates in the clinic and pre-clinical models. Attendees will discuss the current state of pre-clinical in vivo studies and the future opportunities to improve translational clinical relevance for oncology and immuno-oncology therapies.

Your workshop leaders:

Brian Soyer Photo

James Keck
Senior Director, In Vivo Pharmacology & Clinical Lab Services
The Jackson Laboratory

Brian Soper, Ph.D.
Manager of Technical Information Services
The Jackson Laboratory

Organoids and the Transgenic Manipulation of Human Tumor Models

Tuesday, January 22


Rapid advances in therapeutic areas like cancer immunotherapy, has created a need for translational strategies to more effectively guide indication selection, understand mechanisms of resistance and identify biomarkers of response. 3D organoids have presented huge opportunities to bridge the in vitro and in vivo gap. Providing insights, beyond basic descriptors at the cellular level, these models are offering new insights signaling, microenvironments, and cell-type specific behavior.  This workshop this session will look to explore the technical advances in designing these models. It will cover how organoid systems are being further adapted towards applications within the basic and pharmaceutical setting through the use of transgenic and other editing technologies as well as strategies for overcoming remaining issues to use.

Discussions in this session will centre on:

  • How to develop flexible strategies with organoid cultures to maximize predictability and translatability of early discoveries
  • Assessing the translational capability and remaining limitations of organoid cultures
  • Applications of organoids in understanding of disease biology, mechanisms to disease and opening up new avenues for the path to target
  • Cross comparative analyses of data generated in CRISPR/transgenically  edited organoid systems to in vivo systems

Your workshop leader:


Joshua Breunig
Assistant Professor, Board of Governors Regenerative Medicine Institute

Cedars-Sinai Medical Center, UCLAatory